Great Novel Therapeutics Biotech & Medicals
NT$64.00+NT$0.90 (+1.43%)
Great Novel Therapeutics Biotech & Medicals’s quoted price sits in the upper half of its reported 52-week range, 22.71% below the high.
TWO · 6850.TWO · TWD
Stock price, dividends
Quote as of Oct 30, 2026, 05:05 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
BiOptic Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.78% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
BiOptic Inc.’s forward annual dividend is NT$0.50 per share, paid annual. The forward yield is 1.67% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
THE COMPANY BEHIND THE TICKER
BiOptic Inc. specializes as a biotechnology instrumentation firm, crafting scientific tools designed for both laboratory research and clinical applications. Their extensive product line features various instruments, including sophisticated bio-fragment analyzers and PCR thermocyclers. Additionally, they supply essential consumables such as cartridges for DNA, RNA, and protein analysis, alongside quantification kits. The company further provides specialized PCR reagents, encompassing premixed formulas and polymerases. Completing their offerings are diverse diagnostic kits tailored for veterinary, human, and food-related testing. Founded in 1993, BiOptic Inc. is headquartered in New Taipei City, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$64.00+NT$0.90 (+1.43%)
Great Novel Therapeutics Biotech & Medicals’s quoted price sits in the upper half of its reported 52-week range, 22.71% below the high.
NT$16.90NT$0.00 (0.0%)
GenMont Biotech Incorporation’s quoted price sits in the lower half of its reported 52-week range, 14.43% below the high.
NT$18.70-NT$0.15 (-0.8%)
NaviFUS Corp.’s quoted price sits in the lower half of its reported 52-week range, 30.87% below the high.
NT$31.45-NT$0.05 (-0.16%)
NeoCore Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.91% below the high.
NT$20.00-NT$0.50 (-2.44%)
Abnova (Taiwan) Corporation’s quoted price sits in the lower half of its reported 52-week range, 31.39% below the high.
NT$23.00NT$0.00 (0.0%)
LabTurbo Biotech Corporation’s quoted price sits in the lower half of its reported 52-week range, 11.88% below the high.
NT$13.80-NT$0.20 (-1.43%)
MegaPro Biomedical Co., Ltd’s quoted price sits in the upper half of its reported 52-week range, 19.06% below the high.
NT$14.90-NT$0.40 (-2.61%)
Enimmune corporation’s quoted price sits in the lower half of its reported 52-week range, 33.92% below the high.